Printer Friendly

EMPI ANNOUNCES BIOFEEDBACK AND INCONTINENCE DIAGNOSTIC SCREENING TRANSACTIONS, STOCK SPLIT

 ST. PAUL, Minn., May 19 /PRNewswire/ -- Empi, Incorporated (NASDAQ-NMS: EMPI), a medical device manufacturer, announced at the company's annual meeting today that it is acquiring substantially all the assets of privately held Physical Health Devices, Inc. (PHD) of Fort Lauderdale, Fla., a biofeedback company. Empi also has signed a letter of intent to obtain exclusive worldwide distribution rights for a urinary incontinence diagnostic screening system developed by Minneapolis-based MedAmicus Inc.
 In addition, Empi announced that its board of directors approved a two-for-one common stock split.
 Commenting on the product announcements, Donald D. Maurer, Empi president and chief executive officer, said: "Together, these two transactions greatly expand Empi's opportunities -- both domestically and internationally -- and provide us with a full spectrum of diagnostic and behavioral treatment products so that we can continue penetration of our two primary markets, incontinence and rehabilitation."
 Agreement Terms
 Under terms of the agreement with PHD, Empi will acquire substantially all of the company's assets. The price for PHD, with current revenues of approximately $1.5 million, is $2.5 million in Empi stock, to be paid at closing, which is expected to occur by the end of June. Closing is subject to the approval of PHD shareholders and normal due diligence by Empi. A contingent payment of up to $1 million in Empi stock will be made at the end of 1994 if certain agreed upon revenue levels are achieved with the PHD product line.
 The MedAmicus incontinence diagnostic screening system, for which Empi will be the exclusive worldwide distributor, measures pressure in the bladder and urethra through use of fiberoptic catheter. Empi has agreed to provide to MedAmicus an initial debt financing of $500,000 and, based on results of test marketing of the incontinence screening system, two additional debt placements of $500,000 each. The three debt financings are convertible to MedAmicus common stock at conversion prices of $4.25, $5.25 and $6 per share, respectively. Appointment of Empi as the worldwide distributor of this MedAmicus product and provisions of debt financing by Empi are subject to negotiation and the closing of a definitive agreement.
 Incontinence
 The MedAmicus system is designed to diagnose and measure the severity of urge and stress incontinence, and various mixtures of the two. Maurer noted that primary care physicians and incontinence specialists can use it for initial screening, then follow up with comprehensive treatment programs utilizing both EMG biofeedback and the INNOVA(R) Feminine Incontinence Treatment System.
 PHD's incontinence products include a clinical system and a unit for home use. Both products objectively test and measure pelvic muscle rehabilitation, often a key factor in improving continence.
 Maurer stated: "These products are key to Empi's new, highly focused approach to the incontinence market. We are establishing Empi Clinical Services, a new business unit whose mission is to work with primary care physicians, physical therapists and nursing services to develop specialized incontinence diagnostic and treatment centers nationwide."
 EMG Biofeedback
 Physical Health Devices has developed six proprietary products which will complement Empi's offerings for its two primary markets, rehabilitation and incontinence. These products utilize electromyography (EMG) biofeedback, measuring and graphically displaying electrical activity in the muscles to expedite the process of teaching rehabilitation patients how to properly move and control their muscles. Built-in technology enables clinicians to see whether the patient is properly following a prescribed exercise program.
 The rehabilitation products include both clinic and home systems that, through electrode placement, provide biofeedback for any muscle in the body; a belt-like device specifically designed for back injury prevention and rehabilitation; and a range of motion measurement device.
 Maurer said: "We are confident that EMG biofeedback will help save health care dollars through more efficient home and clinic treatment -- particularly in the workers' compensation area, while improving quality of care."
 Stock Split, New Directors
 The stock split announced by Empi today will be effect in the form of a 100 percent stock dividend, payable to shareholders of record at the close of business on May 28, 1993. The new shares will be distributed on June 11, 1993, and will increase the number of common shares outstanding from 4,127,657 to 8,255,314.
 Maurer said: "This stock split, our second in two years, reflects the strong performance of our stock and broadens the market for Empi stock, thereby benefiting both our shareholders and the company." Empi recently reported its 13th consecutive quarter of record sales and earnings gains for the first quarter ended March 31, 1993.
 Also at today's annual meeting, Empi shareholders elected a new member to the company's board of directors. Dr. Kenneth F. Tempero, chairman and chief executive officer of MGI Pharma Inc., was elected to a three-year term on the board. A second new director, Michael J. Fitzpatrick, president and chief executive officer of Network Systems, Inc., has been appointed to complete the term of a recently retired board member.
 Empi develops, manufactures and distributes non-invasive biomedical devices and accessories for electro-therapeutic applications in physical medicine, orthopedic, rehabilitation, urogynecology and neurology markets. The company's shares are traded on the NASDAQ National Market System under the symbol EMPI.
 -0- 5/19/93
 /CONTACT: Diane Rose or Marian Briggs, 612-871-8877, both of Padilla Speer Beardsley; or Timothy Briggs of Empi, 612-639-2330/
 (EMPI)


CO: Empi, Incorporated; MedAmicus, Inc. ST: Minnesota IN: MTC SU:

AL -- MN011 -- 0431 05/19/93 16:05 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 19, 1993
Words:891
Previous Article:PYNG TECHNOLOGIES CORP. ANNOUNCES CORPORATE UPDATE
Next Article:HANNAFORD DECLARES REGULAR QUARTERLY DIVIDEND
Topics:


Related Articles
EMPI ANNOUNCES 1991 SALES AND INCOME RECORDS, AS ANNUAL NET INCOME MORE THAN DOUBLES
MEDAMICUS ANNOUNCES LETTER OF INTENT WITH EMPI, INCORPORATED
EMPI REPORTS RECORD RESULTS FOR SECOND QUARTER AND FIRST HALF
EMPI COMPLETES ACQUISITION OF BIOFEEDBACK COMPANY
EMPI REPORTS STRONG SALES AND EARNINGS GAINS FOR 1993 THIRD QUARTER
MEDAMICUS ANNOUNCES SIGNING OF INVESTMENT AGREEMENT WITH EMPI
EMPI FINALIZES INVESTMENT AND TEST MARKETING AGREEMENT FOR TWO INCONTINENCE PRODUCTS DEVELOPED BY MEDAMICUS, INC.
EMPI EXPECTS FIRST-QUARTER SALES, EARNINGS TO BE BELOW ANALYSTS' ESTIMATES
EMPI ANNOUNCES FIRST-QUARTER SALES, EARNINGS
EMPI, MEDAMICUS UNABLE TO FINALIZE DISTRIBUTION AGREEMENT

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters